Biotech Values

[genisi]

>VPHM been trading +25 minutes at +- $10.50<

It is $8.1 now on this:

Aug 10 (Reuters) - ViroPharma Inc. said (VPHM.O: Quote, Profile, Research) said it and partner Wyeth Pharmaceuticals, a unit of Wyeth (WYE.N: Quote, Profile, Research), decided to end dosing with a drug to treat Hepatitis C virus (HCV) in a mid-stage trial due to safety concerns.

Shares of ViroPharma fell 16 percent to $8.60 in early morning trade on the Nasdaq.

ViroPharma said the drug candidate, HCV-796, was given along with pegylated interferon and ribavirin, which are the standards of care for HCV infection.

This decision follows a review of safety data which shows elevated liver enzyme levels in some patients after eight weeks or more of therapy with the combination, ViroPharma said in a statement.

Exton, Pennsylvania-based ViroPharma said the U.S. Food and Drug Administration has been notified that all patients on triple therapy will now be maintained on only pegylated interferon and ribavirin for the remainder of the clinical study.

ViroPharma said it and Wyeth will analyze data from the study to decide the drug's future. (Reporting by Varsha Tickoo in Bangalore)

http://www.reuters.com/article/marketsNews/idUKBNG28853220070810?rpc=44